Psychedelic drug therapies continue to win over new supporters. But the clock is ticking with our Mental Health Crisis...
Entheon Biomedical
Company Brief
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.
Highlights
Related Articles
Field Trip Psychedelics Inc. Expands Stateside With Psychedelic-Enhanced Psychotherapy Clinic in New York City
Field Trip adds a ketamine-assisted psychotherapy clinic to its operations.
TSI EDITOR |
2020-08-17
New Psychedelic Research Nonprofit Teams with Johns Hopkins University for Real-World Study on Use of Psilocybin Mushrooms
Unlimited Science, a psychedelics non-profit R&D organization, is collaborating with Johns Hopkins.
TSI EDITOR |
2020-08-14
Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results
MindMed reported a net loss of $5.8 million for first 6 months of 2020, has USD $24 million in cash.
TSI EDITOR |
2020-08-14
Psychedelics and Cannabis: Part 2, Industry Overlap
Among publicly listed companies in the psychedelics space, most are psychedelics-cannabis hybrids. It actually makes a lot of sense.
TSI EDITOR |
2020-08-14
Tryp Therapeutics Partners with Albany Molecular Research Inc. to Manufacture a Proprietary Psilocybin-based Drug
Tryp Therapeutics adds a partner to advance its drug manufacturing capabilities.
TSI EDITOR |
2020-08-13
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now